Context Therapeutics (NASDAQ:CNTX) Earns Outperform Rating from Analysts at JMP Securities

JMP Securities initiated coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research report sent to investors on Wednesday morning, MarketBeat reports. The firm issued an outperform rating and a $4.00 price target on the stock.

Several other equities research analysts have also issued reports on CNTX. D. Boral Capital initiated coverage on shares of Context Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $9.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Context Therapeutics in a report on Monday, September 23rd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $6.33.

Context Therapeutics Price Performance

Shares of CNTX opened at $1.08 on Wednesday. The firm has a 50 day simple moving average of $1.47 and a two-hundred day simple moving average of $1.92. Context Therapeutics has a one year low of $0.89 and a one year high of $2.75. The company has a market cap of $81.00 million, a P/E ratio of -1.19 and a beta of 2.10.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). On average, analysts expect that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Great Point Partners LLC bought a new position in Context Therapeutics during the 2nd quarter worth approximately $14,876,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Context Therapeutics during the second quarter worth $10,348,000. Driehaus Capital Management LLC bought a new position in Context Therapeutics during the second quarter worth $4,527,000. Nantahala Capital Management LLC acquired a new position in Context Therapeutics in the second quarter valued at $3,881,000. Finally, Ally Bridge Group NY LLC boosted its position in Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after acquiring an additional 1,160,281 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.